Paper Details

  1. Home
  2. Paper Details

Treatment of Capecitabine Corneal Side Effects With Autologous Blood-derived Serum Eye Drops.

Author: CiancagliniMarco, DI StasoFederico, DI StasoSilvio, GattazzoIrene, LambiaseAlessandro, SalimbeniBeatrice Taurelli, ScuderiGianluca

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A 35-year-old patient with metastatic breast cancer developed bilateral corneal lesions as an ocular side effect of oral chemotherapy with capecitabine and lapatinib. Corneal marginal infiltrates, epithelial, and stromal defects significantly regressed in both eyes after 10 days of treatment with autologous blood-derived serum eye drops. This suggests that autologous blood-derived serum eye drops may be a viable therapeutic option for bilateral corneal lesions caused by capecitabine.
Paper Details　
Original Abstract of the Article :
BACKGROUND/AIM: To describe the clinical progress and management of ocular side effects in a 35-year-old patient with metastatic breast cancer who underwent oral chemotherapy with capecitabine and lapatinib. MATERIALS AND METHODS: Slit lamp evaluation revealed bilateral perikeratic hyperemia, peril...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193336/

データ提供：米国国立医学図書館（NLM）

Treating Capecitabine-Induced Corneal Side Effects with Autologous Blood-Derived Serum

Imagine a camel caravan crossing a harsh desert, where the wind carries sand and the sun beats down relentlessly. Chemotherapy can be like that harsh desert, attacking cancer cells while potentially causing side effects on healthy tissues. This research explores a novel approach to treating corneal side effects induced by the chemotherapy drug capecitabine.

The study describes a patient who developed corneal lesions, like a harsh wind carving patterns into a fragile desert dune, after receiving capecitabine and lapatinib for metastatic breast cancer. The researchers treated the patient with autologous blood-derived serum eye drops, using the patient's own blood to create a serum that promotes healing. It's like finding a natural spring in the desert, offering a source of nourishment and rejuvenation.

Harnessing the Healing Power of Autologous Serum

The study reports significant regression of the corneal lesions after only 10 days of treatment with autologous blood-derived serum eye drops. This suggests that this approach may be a promising option for treating capecitabine-induced corneal side effects. It's like applying a healing balm to the desert, promoting regeneration and restoring balance.

Minimizing Side Effects and Improving Quality of Life

This research highlights the potential of autologous blood-derived serum as a safe and effective treatment for capecitabine-induced corneal side effects. This approach may improve quality of life for patients undergoing chemotherapy, allowing them to continue treatment without compromising their vision. It's like finding a haven in the desert, offering respite from the harsh conditions and promoting overall well-being.

Dr. Camel's Conclusion

This case report demonstrates the potential of autologous blood-derived serum as a therapeutic option for capecitabine-induced corneal side effects. It's a reminder that the desert of medicine is full of hidden oases, and innovative solutions often come from unexpected sources.

Date :
  1. Date Completed 2021-06-18
  2. Date Revised 2021-06-29
Further Info :

Pubmed ID

33910876

DOI: Digital Object Identifier

PMC8193336

Related Literature

Article Analysis
・Effects of capecitabine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.